Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19

  • STATUS
    Recruiting
  • End date
    Apr 28, 2025
  • participants needed
    30
  • sponsor
    University of New Mexico
Updated on 19 February 2024
covid-19
respiratory symptom
acute respiratory syndrome (sars)

Summary

This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.

Description

Primary objectives are as follows:

  1. To provide access to treatment with investigational convalescent plasma to inpatients with documented COIVD-19 infection
  2. To measure NAb titers in an aliquot of the CP administered, to measure the volume of CP administered, and determine whether there is a correlation between the NAb dose (in NAb units/kg body weight, where a unit is the reciprocal of the endpoint NAb titer in the CP multiplied by the volume in ml) and change or lack of change when comparing pre-treatment and day one NAb titers.

Secondary, exploratory objectives are as follows:

  1. To evaluate the safety of convalescent plasma (CP) administration in hospitalized COVID-19 patients
  2. To evaluate viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples before and on days 3, 7, and 14 after CP transfusion
  3. To perform genomic analysis of the SARS-CoV-2 from patients before and after treatment with CP transfusion
  4. Determine cumulative incidence of disease severity (transfer to ICU, type of respiratory support, LOS, and mortality)

Details
Condition Covid 19
Age 18years - 100years
Treatment Convalescent plasma
Clinical Study IdentifierNCT04434131
SponsorUniversity of New Mexico
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be 18 years of age or older
Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing. If COVID-19 test results are pending or done at enrolment, test results must be positive prior to administration of convalescent plasma
Patient (or legally authorized representative, LAR) is willing and able to provide written informed consent and comply with all protocol requirements
For patients unable to consent, consent by the legally authorized representative (LAR) may be obtained by phone

Exclusion Criteria

Female subjects with positive pregnancy test or breastfeeding
Receipt of pooled immunoglobulin in past 30 days
Contraindication to transfusion or history of prior severe allergic reactions to transfused blood products
On ECMO or in refractory shock at entry
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.